ArticleCell reports2017
Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 103 citations in OpenAlex.
- RV144 HIV-1 vaccination impacts post-infection antibody responses.PLoS pathogens · 2020Trial
- Trial
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo.The Journal of experimental medicine · 2026Article
- Article
- Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Vaccine elicitation of HIV-1 neutralizing antibodies against both V2 apex and fusion peptide in rhesus macaques.Cell reports · 2026Article
- Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.Science immunology · 2026Article
- Functional Convergence of Genetically Diverse B-Cell Receptors in Simian-HIV Infected Rhesus Macaques.bioRxiv : the preprint server for biology · 2026Article
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.The Journal of experimental medicine · 2025Article
- An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals.medRxiv : the preprint server for health sciences · 2025Article
- A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.Journal of virology · 2024Article
- Microsecond dynamics control the HIV-1 Envelope conformation.Science advances · 2024Article
- 704/DNA vaccines leverage cytoplasmic DNA stimulation to promote anti-HIV neutralizing antibody production in mice and strong immune response against alpha-fetoprotein in non-human primates.Molecular therapy. Nucleic acids · 2023Article
- An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.International journal of molecular sciences · 2023Article
- Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.Cell reports · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 10 institutions in 2 countries.
Kevin O SaundersDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: kevin.saunders@duke.edu.
Laurent K VerkoczyDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Pathology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: laurent.verkoczy@duke.edu.
Chuancang JiangDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Jinsong ZhangDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Haiyan ChenDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Max HousmanDepartment of Cell Biology, Duke University, Duke University Medical Center, Durham, NC 27710, USA.
Hilary Bouton-VervilleDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Ashley M TramaDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Richard ScearceDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Laura SutherlandDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Sampa SantraBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Amanda EatonDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
Kai XuVaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
Ivelin S GeorgievVaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
M Gordon JoyceVaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Steven G ReedInfectious Disease Research Institute, Seattle, WA 98102, USA.
Andres SalazarOncovir, Inc., Washington, DC 20008, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke School of Medicine, Durham, NC 27710, USA.
Derek W CainDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Mireille CentlivreVaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
Sandra ZurawskiBaylor Institute for Immunology Research, Dallas, TX 75204, USA; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
Gerard ZurawskiBaylor Institute for Immunology Research, Dallas, TX 75204, USA; Vaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
Harold P EricksonDepartment of Cell Biology, Duke University, Duke University Medical Center, Durham, NC 27710, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Disease, Bethesda, MD 20814, USA.
S Munir AlamDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Biomedical Engineering, Duke Pratt School of Engineering, Durham, NC 27710, USA.
Yves LevyVaccine Research Institute (VRI), Inserm U955, Université Paris Est, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil, 94000, France.
David C MontefioriDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine and Immunology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@dm.duke.edu.
Duke University · USNational Institute of Allergy and Infectious Diseases · USAssistance Publique – Hôpitaux de Paris · FRBaylor University · USBeth Israel Deaconess Medical Center · USDuke University Hospital · USHôpital Albert-Chenevier · FRInfectious Disease Research Institute · USOncovir (United States) · USPratt Institute · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MDesign Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MMPER broadly neutralizing antibody knockin mice to study anti-HIV Bcell responsesR01AI087202 · NIAID · SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE · PI VERKOCZY, LAURENT KARL · 2010 to 2022
$5.5MDissection of polyreactivity and neutralization activity of HIV-1 AbsR01AI118571 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R., VERKOCZY, LAURENT KARL · 2016 to 2020
$3.2MNIAID NIH HHS P01 AI131251NIAID NIH HHS R01 AI087202NIAID NIH HHS R01 AI118571NIAID NIH HHS R01 AI120801NIAID NIH HHS UM1 AI100645
Abstract
The events required for the induction of broad neutralizing antibodies (bnAbs) following HIV-1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of concept would be critical. Here, we describe the induction of plasma antibodies capable of neutralizing heterologous primary (tier 2) HIV-1 strains in one macaque and two rabbits. Env immunogens were designed to induce CD4 binding site (CD4bs) bnAbs, but surprisingly, the macaque developed V1V2-glycan bnAbs. Env immunization of CD4bs bnAb heavy chain rearrangement (V
Indexed as
AIDS VaccinesAmino Acid SequenceAnimalsAntibodies, NeutralizingDisease Models, Animalenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1HIV AntibodiesImmunizationMacaca mulattaMicePolysaccharidesProtein MultimerizationRabbitsAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesPolysaccharidesbroadly neutralizing antibodiesCH103CH505HIV vaccineknockin mice
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.